Restoring post-prandial insulin release in type 2 diabetes.
Tight blood glucose control is a primary aim of type 2 diabetes treatment. Combining metformin with the amino acid derivative, nateglinide, tackles both beta cell dysfunction and insulin resistance, and produces a greater decrease in haemoglobin A1c levels than treatment with either drug alone.
Andrews
John
J
Whiteabbey Hospital, Newtownabbey, Belfast BT37 9RH.
D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D008687:Metformin / Q000627:therapeutic use*; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019518:Postprandial Period
D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D000077715:Nateglinide; D010649:Phenylalanine; D008687:Metformin